01 5Breztri
02 4Cortiment
03 8Pulmicort
04 2Pulmicort
05 8Symbicort
06 5Symbicort
07 5Uceris
Budesonide, Glycopyrronium and Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 2
Growth (%) : 1,300
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 0
2019 Revenue in Millions : 213
Growth (%) : -100
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 996
2019 Revenue in Millions : 1,466
Growth (%) : -32
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 8
2019 Revenue in Millions : 5
Growth (%) : 70
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,721
2019 Revenue in Millions : 2,495
Growth (%) : 9
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 6
2019 Revenue in Millions : 11
Growth (%) : -48
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 4
2020 Revenue in Millions : 5
Growth (%) : -31
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 962
2020 Revenue in Millions : 996
Growth (%) : -3
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 2,728
2020 Revenue in Millions : 2,721
Growth (%) : 0
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 4
2020 Revenue in Millions : 7
Growth (%) : -42
LOOKING FOR A SUPPLIER?